Condition (MeSH)
Hemochromatosis
ClinicalTrials.gov lists 54 trials for Hemochromatosis or a narrower condition beneath it. National Heart, Lung, and Blood Institute (NHLBI) has the most among industry and government lead sponsors, with 5.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
54 of the 54 trials are tagged with Hemochromatosis itself; the rest are tagged with a narrower condition beneath it.
When did Hemochromatosis trials start? (25)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2023 | 2 |
| 2022 | 2 |
| 2021 | 1 |
| 2020 | 2 |
| 2018 | 2 |
| 2017 | 3 |
| 2016 | 1 |
| 2015 | 4 |
| 2014 | 1 |
Showing 10 of 25 earlier years.
No forecast is made for this condition: it averages 1.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hemochromatosis trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 2 |
| Phase 2 | 11 |
| Phase 2/3 | 1 |
| Phase 3 | 5 |
| Phase 4 | 2 |
| Not applicable | 9 |
| Observational | 22 |
How many Hemochromatosis trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 4 |
| Active, not recruiting | 2 |
| Completed | 36 |
| Terminated | 4 |
| Withdrawn | 2 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hemochromatosis trials? (7)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | 5 |
| Novartis Pharmaceuticals | 3 |
| Bond Biosciences | 2 |
| Lipomed | 2 |
| ApoPharma | 1 |
Showing 5 of 7 sponsors.
Interventions as named in the registry (15)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Deferoxamine mesylate only | 5 |
| Deferasirox FCT | 4 |
| Deferiprone pill | 3 |
| BBI-001 | 2 |
| Liver biopsy | 1 |
Showing 5 of 15 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Hemochromatosis trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Sickle cell anaemia with crisis | 21 | 1 |
| Pyrexia | 9 | 2 |
| Cerebrovascular accident | 6 | 1 |
| Cholelithiasis | 6 | 2 |
| Iron overload | 5 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Hemochromatosis? (113)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Hepcidin and Iron in Health and Disease. | Annual review of medicine | 2023 | Yes |
| Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial. | The lancet. Gastroenterology & hepatology | 2023 | Yes |
| Iron as an emerging therapeutic target in critically ill patients. | Critical care (London, England) | 2023 | Yes |
| The effect of a natural polyphenol supplement on iron absorption in adults with hereditary hemochromatosis. | European journal of nutrition | 2022 | Yes |
| Identification of novel non-HFE mutations in Chinese patients with hereditary hemochromatosis. | Orphanet journal of rare diseases | 2022 | Yes |
Showing 5 of 113 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.